Regulators must intervene to drive up the quality and impact of patient safety reporting

The ambitions of Patient Safety and ongoing Pharmacovigilance are quite clear - making drugs and therapies as safe as they can be, so that they deliver ever better outcomes. And yet this entire endeavour is threatened by the enormous complexity in capturing meaningful, high-quality insights and acting on them swiftly. Today, tech vendors are promising the world with AI. Leave the chaos as it is, and let AI make sense of it, they say. But it is not that simple. Until regulators insist that better data is captured at source, and until the entire industry understands that AI is not a simple fix to the complexity problem, Safety functions and their patients will be no better off. In this hard-hitting article, illustrated by clear examples of what's still going wrong, Qinecsa's Daniel O'Keeffe explains why it's time for a major shift in approach to the problem of fragmented patient safety data. Drawing on the persisting challenges affecting pharma companies today, he will explain.